(VVUS) |
| 0 (0%) 01-13 20:29 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.43 |
| Resistance 1: | 0.30 |
| Pivot price: | 0.20 |
| Support 1: | 0.10 |
| Support 2: | 0.08 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Mon, 26 Sep 2022
Vertex Ventures US Raises $200 Million Third Fund to Double-down on high-conviction approach to venture capital - Business Wire
Mon, 03 Feb 2020
VVUS: ZenPep Deal Demonstrates PERT Interest - Zacks Small Cap Research
Mon, 09 Nov 2015
Are Takeda's 900 Contrave reps worth it? Maybe not, analyst says - Fierce Pharma
Mon, 03 Aug 2015
Can a dwindling rep tally keep Vivus' obesity med in the game? - Fierce Pharma
Thu, 18 Sep 2014
Drug Stock Goes Bananas After Updated Approval Of Its Fast-Acting Erectile Dysfunction Pill - Business Insider
Mon, 13 May 2013
Elan buys share of Theravance royalties on new drug for $1B; Vivus bulks up its board in anticipation of proxy fight - Fierce Pharma
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
